Trusted Scientific Resources on Rare Diseases Research

At Travere Global Medical Affairs, we are dedicated to scientific exchange, including sharing up-to-date scientific insights and resources with healthcare professionals.

The goal is to provide educational resources ranging from publications and expert-led podcasts to recent congress data and relevant medical information.

About us

FDA Approves Medicine for FSGS

On April 13, 2026, the FDA approved our medicine to reduce proteinuria in adults and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome (Presence of nephrotic syndrome includes proteinuria >3.5 g/24h [adults] or UPCR >2.0 g/g [pediatric patients <18 years of age], serum albumin <3.0 g/dL, and edema).

For more information, read our Press Release.

Read now

MA-SP-26-0003 | April 2026

Path 2 Progress: Advancing FSGS Management Together

Join Path 2 Progress, a series of live, discussion-driven meetings across the U.S., to deepen your scientific expertise, explore the evolving treatment landscape, and help shape the future of FSGS care

Learn more

MA-DS-26-0019 | April 2026

New 2025 IgAN/IgAV Guidelines from KDIGO

On September 18, 2025, the Kidney Disease Improving Global Outcomes (KDIGO) organization released the KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy and IgA Vasculitis.

Marking a turning point in glomerular disease care, the new guidelines incorporate evidence from randomized controlled trials through August 2024.

Learn more

MA-DS-25-0096 | September 2025

Webinar

The Dual Impact of Sparsentan on Inflammation and Proteinuria in IgA Nephropathy

Travere partnered with GlomCon on one of their Clinical Trial Series webinars. This webinar focused on sparsentan in IgA nephropathy.

Learn more

MA-SP-25-0168 | November 2025

Travere at ASN Kidney Week 2025

American Society of Nephrology (ASN) Kidney Week 2025

Kidney Week 2025 is the annual meeting of the American Society of Nephrology (ASN). Travere Therapeutics was excited to participate in ASN Kidney Week 2025 and engage with nephrology leaders from around the world.

Learn more

MA-DS-25-0077 | November 2025

Explore our science

Publication NephrologyIgAN

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial

The Lancet – 2023

Publication NephrologyFSGSIgAN

Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy

Drugs of the Future – 2020

Publication NephrologyFSGSIgAN

Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease

Clinical Science – 2024

Publication NephrologyFSGS

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the PARASOL Initiative

Future Rare Diseases – 2025

See all publications

Summary NephrologyIgAN

Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti‑inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study

15th International Podocyte Conference and ISGD Meeting – 2025

Learn more

Summary NephrologyIgAN

Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial

62nd European Renal Association (ERA) Congress 2025 – 2025

Summary NephrologyFSGS

Sparsentan vs. Irbesartan in Pediatric Patients with Focal Segmental Glomerulosclerosis (FSGS) in the Phase 3 DUPLEX Trial

American Society of Nephrology (ASN) Kidney Week 2025 – 2025

Summary NephrologyFSGS

Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk

American Society of Nephrology (ASN) Kidney Week 2025 – 2025

See all posters & presentations

Podcast Episode NephrologyIgAN

Insights from the SPARTAN Study

In this episode of the RKD Show, Drs. Jonathan Barratt and Shikha Wadhwani discuss the efficacy, safety, and biomarker findings from the Phase 2 SPARTAN study.

Listen now

MA-DS-25-0105 | October 2025

Podcast Episode NephrologyFSGS

From Podocyte to Patient: The Pathophysiology of FSGS

In this episode of the RKD Show, Drs. Tobias Huber and Chris Gisler take a deep dive into the critical role of podocytes in maintaining glomerular function and their central involvement in the development and progression of FSGS.

Listen now

MA-DS-25-0105 | October 2025

Travere and National Kidney Foundation Collaboration

Podcast Episode NephrologyFSGSIgAN

Life as a Nephrology Professional – Milestones in IgAN & FSGS: Advancing Understanding and Possibilities

Drs. Osama El Shamy and Anna Gaddy, PA Elisha Shelton, and Patient Advocate Michael Phillips discuss the pathophysiology of IgA nephropathy and FSGS, recent advancements in IgA nephropathy and FSGS clinical trials, and the patient experience in FSGS.

Listen now

MA-DS-25-0105 | October 2025